Page 54 - 2014 Printable Abstract Book
P. 54
collaboration among 5 laboratories that were conducting biomarker analysis. (Work supported under
Contract HHS0100200100004I, HHSO10033005T with BARDA within the Office of the Assistant Secretary
for Preparedness and Response in the U. S. Department of Health and Human Services.)
(S1003) Biodosimetry Needs in the Aftermath of Radiological or Nuclear Terrorism.
Brooke Buddemeier, Lawrence Livermore National Laboratory, Livermore, CA
In support of the Department of Homeland Security’s Science and Technology Directorate,
Lawrence Livermore National Laboratory has undertaken detailed consequence modeling of a nuclear
detonation in several modern U.S. cities that obtain insight into the nature and distribution of injuries and
support community preparedness activities. Atmospheric dispersion and prompt effects models are
important tools for planning an initial response to a nuclear detonation; however many current predictive
models make some overly simplified assumptions. The analysis used for this study provided more realistic
methods of estimating exposure by accounting for the presence of different building types to provide
radiation exposure ranges, numbers of potential casualties, and combined injury distributions that may
help biodosimeter developers acquire an improved understanding of the operational environment and
need. Results indicate that although high levels of casualties and extensive destruction may be
unavoidable, both casualties and secondary effects can be significantly reduced with proper planning,
equipment, training, biodosimetry, and medical countermeasure.
(S1004) Point of Care Radiation Biodosimeter based on Novel Protein Biomarker Panels in Humans and
Non-Human Primates. David E. Cooper, SRI International, Menlo Park, CA
We are developing a point of care radiation biodosimeter based on the sensitive detection of a
panel of proteins measured from a finger prick blood sample. In the feasibility phase we demonstrated,
using tandem mass spectrometry and immunoassay techniques, several panels of 3 to 5 radiation
responsive proteins that classify non-human-primates (NHP) following acute exposure to x-ray or gamma
radiation. Highly accurate (>96%) classification of 300 samples obtained at 5 time points from 60 animals
into two exposure groups of interest (either above or below 4 Gy) is achieved using several different
classification schemes with false negative and false positive rates of around 3%. Similar panels of protein
markers that are suitable for use in humans were used to classify 54 samples from 18 human radiotherapy
patients receiving fractionated Total Body Irradiation (TBI) doses of x-rays, plus 82 samples from healthy
controls, with >95% accuracy and false negative and false positive rates of 5.9% and 3.4% respectively.
Currently in the product development phase we have developed simple to use lateral flow assays for 3
potential protein markers using up converting phosphor particles as a reporter. Additionally we have
developed a prototype handheld reader for use by first responders. The goal of this project is to have an
FDA cleared and CLIA waived invitro diagnostic assay. Acknowledgement. This project has been funded in
whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority
(BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary,
Department of Health and Human Services, under Contract No. HHSSO10020100007C to SRI International.
52 | P a g e
Contract HHS0100200100004I, HHSO10033005T with BARDA within the Office of the Assistant Secretary
for Preparedness and Response in the U. S. Department of Health and Human Services.)
(S1003) Biodosimetry Needs in the Aftermath of Radiological or Nuclear Terrorism.
Brooke Buddemeier, Lawrence Livermore National Laboratory, Livermore, CA
In support of the Department of Homeland Security’s Science and Technology Directorate,
Lawrence Livermore National Laboratory has undertaken detailed consequence modeling of a nuclear
detonation in several modern U.S. cities that obtain insight into the nature and distribution of injuries and
support community preparedness activities. Atmospheric dispersion and prompt effects models are
important tools for planning an initial response to a nuclear detonation; however many current predictive
models make some overly simplified assumptions. The analysis used for this study provided more realistic
methods of estimating exposure by accounting for the presence of different building types to provide
radiation exposure ranges, numbers of potential casualties, and combined injury distributions that may
help biodosimeter developers acquire an improved understanding of the operational environment and
need. Results indicate that although high levels of casualties and extensive destruction may be
unavoidable, both casualties and secondary effects can be significantly reduced with proper planning,
equipment, training, biodosimetry, and medical countermeasure.
(S1004) Point of Care Radiation Biodosimeter based on Novel Protein Biomarker Panels in Humans and
Non-Human Primates. David E. Cooper, SRI International, Menlo Park, CA
We are developing a point of care radiation biodosimeter based on the sensitive detection of a
panel of proteins measured from a finger prick blood sample. In the feasibility phase we demonstrated,
using tandem mass spectrometry and immunoassay techniques, several panels of 3 to 5 radiation
responsive proteins that classify non-human-primates (NHP) following acute exposure to x-ray or gamma
radiation. Highly accurate (>96%) classification of 300 samples obtained at 5 time points from 60 animals
into two exposure groups of interest (either above or below 4 Gy) is achieved using several different
classification schemes with false negative and false positive rates of around 3%. Similar panels of protein
markers that are suitable for use in humans were used to classify 54 samples from 18 human radiotherapy
patients receiving fractionated Total Body Irradiation (TBI) doses of x-rays, plus 82 samples from healthy
controls, with >95% accuracy and false negative and false positive rates of 5.9% and 3.4% respectively.
Currently in the product development phase we have developed simple to use lateral flow assays for 3
potential protein markers using up converting phosphor particles as a reporter. Additionally we have
developed a prototype handheld reader for use by first responders. The goal of this project is to have an
FDA cleared and CLIA waived invitro diagnostic assay. Acknowledgement. This project has been funded in
whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority
(BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary,
Department of Health and Human Services, under Contract No. HHSSO10020100007C to SRI International.
52 | P a g e
